Use of Technical Documentation Under MDR for International Registration
This article outlines which parts of the EU MDR technical documentation are most frequently used for international registrations in critical markets. The content applies not only to EU manufacturers but also to any manufacturer whose technical documentation has been reviewed by an EU Notified Body (above Class I). In general, revisions to EU technical documentation do not affect international registrations unless they involve critical changes such as labelling, intended use, or raw materials, as defined by each market’s change‑notification guidance.
Annex II 1.1 Device Description and Specification
Many manufacturers with EU dossier lack a clear, descriptive document for international submissions. Authorities often cannot understand what the device does and what its key features are. A well‑structured device description is essential.
Modification rewarded: high
Possibility of deficiency: high
Annex II 1.2 Reference to Previous and Similar Generations
This section often requires rewriting for international markets. Many countries have equivalence device or rather change‑registration policy. Manufacturers should prepare a clear comparison table with supporting evidence. Differences must be reflected consistently across V&V, risk management, quality control, and change assessment.
Modification rewarded: high
Possibility of deficiency: high
Annex II 2 Labelling
IFU requirements differ significantly across markets. An English IFU that consolidates global requirements is often the most efficient approach. Label requirements vary even more widely, especially due to language and country‑specific symbols, so separate international labels are recommended to simplify revisions.
Modification rewarded: high
Possibility of deficiency: low
Annex II 3 Manufacturing Information
EU MDR Annex II.3 focuses on device‑specific manufacturing details, while IMDRF ToC Chapter 6 provides a globally harmonized QMS framework used for multi‑country submissions. As more regulators adopt IMDRF structures, manufacturers increasingly rely on this global QMS documentation to streamline approvals. However, several markets still require their own national QMS certifications—such as MDSAP (Canada), Japan QMS, Taiwan QSD, Ukraine QMS, and FDA’s QSMR—which require separate applications and inspections.
Modification rewarded: medium
Possibility of deficiency: medium
Annex II 4 GSPR
Most countries request either a local Essential Principles checklist or a standards list. Manufacturers may submit the full GSPR or a simplified version depending on the market.
Modification rewarded: low
Possibility of deficiency: low
Annex II Risk Management File
Authorities rarely specify whether they require the risk plan, risk analysis, or risk report. A simplified risk management file is generally sufficient for international submissions.
Modification rewarded: high
Possibility of deficiency: low
Annex II Verification & Validation (V&V)
Typical V&V elements include:
-
Sterilization
-
Shelf life
-
Packaging
-
Biocompatibility
-
Usability (IEC 60601‑1‑6)
-
Software (IEC 62304)
-
Electrical safety and EMC
This is often the most challenging area for EU manufacturers, who assume MDR‑approved reports automatically satisfy international requirements. Manufacturers must understand exactly what each market expects—sometimes a general V&V summary is enough, while other times full physical or chemical testing is required. Evaluation report must cover the entire device, not only change‑specific deltas. For change registrations, worst‑case configurations and change items must be clearly addressed.
Modification rewarded: high
Possibility of deficiency: high
Annex III PSUR
Annex XIV Part B PMCF
Annex XIV SRRC / SSCP
EU MDR reports such as PSUR, PMCF, and SSCP are not globally mandatory but are widely accepted as high‑quality evidence. PMCF‑type ongoing clinical data is increasingly expected in China, Japan, Australia, and Brazil.
Modification rewarded: high
Possibility of deficiency: low
Chapter VI & Annex XV Clinical Evaluation and Clinical Investigations
EU MDR clinical evaluation and clinical investigation requirements are widely respected internationally and often considered more stringent than many national frameworks. However, each country has its own clinical evidence requirements that must be assessed individually.
Modification rewarded: high
Possibility of deficiency: high
Annex IV EC Declaration of Conformity
For manufacturers with CE certificates or equivalent declarations, this document often accelerates international submissions. Some markets also request the MDD/MDR certificate or a Free Sales Certificate issued by local EU authorities.
Modification rewarded: N/A
Possibility of deficiency: high